GLP-1RA receptor agonists and SGLT2 inhibitors beneficial for managing type 1 diabetes – DiabetesTimes.co.uk

A new study has found an association between good type 1 diabetes management and the use of GLP-1RA receptor agonists and SGLT2 inhibitors in real-world practice.
During the experiment, a team of researchers examined the health outcomes of 104 adults living with type 1 diabetes who either used GLP-1RA receptor agonists (GLP-1RAs) or SGLT2 inhibitors (SGLT2is).
After one year of therapy, they found that GLP-1RA users had significant reductions in weight, HbA1c and total daily dose of insulin.
SGLT2i users also had statistically significant reductions in HbA1c and basal insulin, the study has reported.
The results state: “GLP-1RA users compared to SGLT2i users had greater reduction in weight (P = .027) while HbA1c reduction was comparable between the groups.
“Over a mean total duration of use of 29.5 months/patient for both groups, more SGLT2i users experienced diabetic ketoacidosis (DKA) (12.8 per cent vs 3.9 per cent).”
They added: “Therapy was discontinued because of adverse events 26.9 per cent of the time for GLP-1RA users vs 27.7 per cent for SGLT2i users.
“GLP-1RA and SGLT2i use in type 1 diabetes is associated with clinically relevant benefits. DKA remains a clinical concern with SGLT2i use, requiring careful selection and monitoring, with the risk to benefit ratio of treatment evaluated at an individual level.”
To read the study, click here.
Register an account or login to comment
Diabetes UK issues latest guidance on coronavirus
People with diabetes urged to be ‘particularly stringent’ amid COVID-19 pandemic
NHS Drug Tariff approval for FreeStyle Libre System
Updated metformin and B12 guidance published
Criticism over Eatwell Plate amid calls for low carb approach
Type 1 man no longer requires insulin
Man commended for living with diabetes for 80 years
Warning over Lucozade sugar reduction
FreeStyle® Libre 2 includes optional real-time alarms
Novo Nordisk UK launches Ozempic® (semaglutide)
Empagliflozin reduces risks of chronic kidney disease, study reports
SGLT2 inhibitors reduces heart failure and increases lifespan of people with cancer and diabetes
GLP-1RA receptor agonists and SGLT2 inhibitors beneficial for managing type 1 diabetes
Long-term cardiovascular problems triggered by gestational diabetes, study demonstrates
Antihyperglycaemic drugs are beneficial for people with type 2 diabetes and chronic obstructive pulmonary disease
Global scientific experts to advise on £50 million investment into type 1 diabetes research
Once-weekly semaglutide helps combat teenage obesity, evidence identifies
Retired optometrist puts diabetes technologies under the spotlight in latest Big Interview
Welsh type 2 diabetes patients are missing out on vital free education
New book on type 1 diabetes technology published
Diabetes Inpatient Specialist Nurse
Paediatric Diabetes Dietitian
Band 7 Midwife in Diabetes
Advanced Podiatrist in Diabetes
Paediatric Diabetes Dietitian
Diabetes Specialist Nurse
Consultant in Diabetes and Endocrinology
Diabetes Support Worker (South West & South Central)
Digital Engagement Officer (South West & South Central)
Diabetic Specialist Midwife

The Diabetes Times © 2022

source